Chapter 38 Exercises: Peptide Regulation

These exercises train one skill: reading a regulatory statement without letting it act as an evidence statement. Most of them ask you to classify, distinguish, or rewrite rather than to recall.

No answers are provided here. Several items have more than one defensible response, and the defense is the work.

Items marked † are extended — they take longer, usually involve looking something up, and are suitable for written work or seminar preparation.

A standing rule for every item in this file: nothing you write here is legal advice, to yourself or to anyone else. Where an item asks about rules, it is asking you to describe a structure, not to determine what is permitted for any particular person in any particular place. If an exercise makes you want to know what you personally are allowed to do, that is a question for the current rules of your own jurisdiction and someone qualified to read them — not for a homework answer.

Group 1 — What approval means (§38.1)

A. Write the definition of an approval in one sentence, from memory, and then check it against §38.1. Which clause did you drop? Almost everyone drops the same one.

B. The sentence "tirzepatide is FDA approved" is incomplete. State what is missing and rewrite it twice — once so that it is defensible, and once so that it is defensible and useful to someone deciding whether their insurance will cover it (Chapter 12).

C. List the four things an approval is not, from §38.1. For each one, write a single sentence describing a real situation in which someone would be misled by assuming the opposite.

D. A label lists an adverse event at a rate of 3%. Explain, in two sentences, what population that number describes and why it may not describe the person reading it.

E. † Find the approved label for any peptide drug and read the "Indications and Usage" section only. Write down (1) the exact indication wording, (2) the population qualifiers, and (3) any condition attached. Then write one sentence on how the drug is described in consumer advertising and name the gap.

Group 2 — The forty-amino-acid line (§38.2)

F. State the forty-amino-acid line in one sentence, with its jurisdiction. Then explain, in one more sentence, why "biologic" and "drug" are not descriptions of how a molecule behaves.

G. Sort these onto the correct side of the line, and give the residue count for each: oxytocin, BPC-157, teriparatide, semaglutide, tirzepatide, insulin, growth hormone. Which one is closest to the line, and how much room does it have?

H. Explain the difference between a generic application and a biosimilar application in terms a non-scientist would follow. Your explanation must include why the difference exists — that is, why the generic route cannot simply be extended to biologics.

I. Insulin is roughly 5,800 Da and semaglutide is roughly 4,100 Da, and they fall on opposite sides of the line. Explain how that is possible, and what it tells you about what the line actually measures.

J. † Trace the consequence chain: molecule length → application type → follow-on pathway → number of competitors → price → access. Write it as a numbered chain of five to seven steps, and mark which steps are legal facts, which are economic predictions, and which are contested.

K. Insulin was deemed a biological product under a transition effective in March 2020. Explain what that changed and what it did not change. (Hint: the molecule did not change.)

L. † Argue the counterfactual. If the line had been drawn at 30 amino acids instead of 40, which molecules in this book would move, and what would the consequences plausibly be? Be explicit about where you are speculating.

Group 3 — The pathway (§38.3)

M. Name each phase of the development pathway and, in one clause each, state the question that phase is designed to answer.

N. An IND is not an approval. Explain what it is, and why the distinction matters when a company press release says a compound "has been cleared by the FDA."

O. Chapter 10 established that attrition is concentrated where human efficacy is first tested. Explain why that placement is not a flaw in the system but a consequence of what the earlier stages can and cannot tell you.

P. Accelerated approval defers confirmatory evidence rather than waiving it. Describe what has to be true for that trade to be a good one, and name one way it can fail.

Q. † A product page cites three trial registry numbers as evidence that a compound "is in clinical trials." Write the four questions you would ask before treating that as meaningful, and explain what a registry entry actually documents.

Group 4 — The five meanings (§38.4)

R. Write out the five meanings of "not FDA approved" from memory. Then rank them from strongest negative signal about the molecule to weakest, and defend the ranking.

S. Assign a case number to each: a peptide with no filing history; a face serum ingredient; a registered medicine in one country absent from another; an approved drug used for an unlisted condition; a compound whose application was withdrawn mid-review.

T. Case (3) has two very different underlying stories. Name both and describe how you would try to tell them apart for a specific compound.

U. † Take a compound you have actually seen marketed and determine which of the five cases applies to it in your own jurisdiction. Document what you checked and what you could not determine. "Could not determine" is an acceptable and common result; say so explicitly if that is where you land.

V. Explain, in three sentences, why BPC-157's ❌ rating in Chapter 17 does not rest on its regulatory status — and name the specific thing that would change the rating.

W. Someone says: "It's not approved, but it's not banned either, so it's in a legal gray area." Identify the two separate confusions in that sentence and correct both.

Group 5 — Off-label and compounding (§38.5, §38.6)

X. State the asymmetry between off-label prescribing and off-label promotion, and explain the reasoning behind it in your own words. Then name one cost that the asymmetry imposes.

Y. "Off-label is not a synonym for unsupported." Give one plausible example of a well-supported off-label use and one of a thinly supported one, and explain how a reader could tell them apart.

Z. Distinguish 503A from 503B on five dimensions. Then identify the one row that is identical across both and explain why it is the most important row on the table.

AA. Describe the shortage mechanism: what a shortage listing permits, and what happens to that permission when the shortage is declared resolved. Do not attach dates you have not verified.

AB. † A compounded product contains the same active molecule as an approved drug. List four ways it may nonetheless be a different product, and for each one, explain the specific clinical risk that difference creates (Chapter 19).

AC. A clinic's website says "physician-prescribed, pharmacy-compounded, made in the USA." Rewrite that sentence so that it is equally accurate and carries no implication of premarket review.

Group 6 — Research chemicals, supplements, and doping (§38.7, §38.8)

AD. Explain why "for research use only" is a liability posture rather than a regulatory category. Your answer should include what the phrase does for the seller and what it fails to do for the buyer.

AE. DSHEA created a category with no premarket approval requirement. Explain why that fact alone does not make every peptide sellable as a supplement.

AF. State the S0 rule in one sentence. Then explain why "it isn't on the banned list" is usually wrong by construction, using the distinction between a list of names and a rule about a property.

AG. † BPC-157 is rated ❌ for its healing claims and is prohibited under S0. Write a paragraph explaining to a skeptical athlete why those two facts are independent — and why the independence means the prohibition is not evidence that the compound works.

AH. Under S0's logic, a compound moving toward approval becomes less prohibited, not more. Explain why, and say whether you find that result sensible.

Group 7 — Patchwork, status, and evidence (§38.9, §38.10)

AI. List four distinct reasons two agencies might reach different conclusions about the same molecule. For each, say what a reader could look at to find out whether that reason applies.

AJ. † "Approved in [country]" is a fact worth knowing and a poor substitute for the evidence. Write a 300-word explanation of that sentence for someone who has just been shown a foreign registration certificate as proof that a compound works.

AK. Reproduce the two-by-two grid from §38.10 and populate each cell with a different compound or claim from this book. Which cell took you longest, and what does that tell you?

AL. Nesiritide was approved in 2001 and a large outcome trial published in 2011 found no benefit on the endpoints that mattered most. Argue both sides: that the 2001 approval was a reasonable decision on the evidence available, and that it was a cautionary example. Then say which you believe.

AM. † The chain in §38.10 — no submission, because no funding, because no patentable position — is a structural claim about drug economics. Steelman it, then identify the one inference it does not license, and explain why that inference is the one gray-market marketing always makes.

AN. Write the two-sentence version of this chapter's thesis, in your own words, without using the words "approved" or "evidence" in the first sentence.

Group 8 — Dossier work (Field 10)

AO. Complete Field 10 for every compound in your dossier: approved anywhere and for what indication; which of the five cases applies where it is not; prohibited in tested sport and under which category and List year; and how it is actually being sold. Date the entry.

AP. † For each compound, put the Field 10 entry and the evidence rating side by side in separate columns and look across the rows. Identify every mismatch — approved-but-thin, unapproved-but-simply untested — and write one sentence per mismatch explaining what produced it.

AQ. Field 10 took five chapters to complete. Name the question each of those chapters answered, and say which of the five you find hardest to answer for the compounds you care about.

AR. † Audit yourself. Find one place in your dossier where a regulatory fact moved an evidence rating, in either direction. Write down what moved you and why it should not have. If you genuinely cannot find one, write instead about which direction you would be most likely to slip in, and what would make you notice.